All Releases
 |
NeurogesX to Present at Upcoming Cowen and ROTH Conferences
Mar 1, 2010
|
9.0 KB |
|
| |
SAN MATEO, Calif., March 1, 2010 /PRNewswire via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at two upcoming conferences: Cowen and Co...
|
|
NeurogesX to Present at BIO CEO & Investor Conference
Feb 4, 2010
|
8.7 KB |
|
| |
SAN MATEO, Calif., Feb 04, 2010 /PRNewswire via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 12th Annual BIO CEO & Investor Con...
|
|
NeurogesX Announces Management Team Promotions
Feb 4, 2010
|
9.8 KB |
|
| |
SAN MATEO, Calif., Feb 04, 2010 /PRNewswire via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that three management team members have received promotions:
Stephen Ghiglieri has been named Executive Vice President, Chief...
|
|
NeurogesX to Present at J.P. Morgan Health Care Conference
Jan 7, 2010
|
8.7 KB |
|
| |
SAN MATEO, Calif., Jan 07, 2010 /PRNewswire via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 28th Annual J.P. Morgan Healthcare...
|
|
NeurogesX to Present at Piper Jaffray Health Care Conference
Nov 24, 2009
|
8.7 KB |
|
| |
SAN MATEO, Calif., Nov 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 21st Annual Piper Jaffray...
|
|
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
Nov 24, 2009
|
9.5 KB |
|
| |
SAN MATEO, Calif., Nov 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the appointment of John A. Orwin to its Board of Directors, effective November 19, 2009. Mr. Orwin is a 20-year sales...
|
|
NeurogesX to Hold Conference Call to Discuss FDA Approval of Qutenza® (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Nov 17, 2009
|
9.8 KB |
|
| |
SAN MATEO, Calif., Nov 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX) announces that it will hold a conference call today at 8:30a.m. ET (5:30a.m. PT) to discuss the U.S. Food and Drug Administration (FDA) approval of Qutenza(TM) (capsaicin) 8% patch, the first and only product containing prescription stre...
|
|
NeurogesX Receives FDA Approval of Qutenza® (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Nov 16, 2009
|
12.7 KB |
|
| |
SAN MATEO, Calif., Nov 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX) announced today that the U.S. Food and Drug Administration (FDA) has approved Qutenza(TM) (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherp...
|
|
NeurogesX Reports Third Quarter 2009 Results
Nov 6, 2009
|
18.3 KB |
|
| |
SAN MATEO, Calif., Nov 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- 3Q09 Corporate Highlights:
-- Completed transfer of Qutenza(TM) E.U. Marketing Authorization to
Astellas Pharma Europe Ltd.
-- Made significant progress in commercial readiness activities
-- Expanded management team to include VP Sales; Seni...
|
|
NeurogesX Expands Commercial Operations Leadership Team
Nov 5, 2009
|
11.9 KB |
|
| |
SAN MATEO, Calif., Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the expansion of its U.S. commercial operations team to include a Vice President of Sales, Senior Director of Marketi...
|
|
NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Oct 30, 2009
|
9.2 KB |
|
| |
SAN MATEO, Calif., Oct 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Friday, November 6, 2009 at 9:00 a.m. ET (6:00 a.m. PT) to report results for its t...
|
|
NeurogesX to Present at Two November Conferences
Oct 29, 2009
|
9.3 KB |
|
| |
SAN MATEO, Calif., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at two upcoming conferences in N...
|
|
NeurogesX to Present at JMP Securities Healthcare Focus Conference
Oct 1, 2009
|
9.1 KB |
|
| |
SAN MATEO, Calif., Oct 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the Fourth Annual JMP Securit...
|
|
NeurogesX to Present at UBS Global Life Sciences Conference
Sep 17, 2009
|
8.8 KB |
|
| |
SAN MATEO, Calif., Sept 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences...
|
|
NeurogesX to Present at Upcoming Fall Conferences
Sep 2, 2009
|
9.2 KB |
|
| |
SAN MATEO, Calif., Sept 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at two upcoming conferences in ...
|
|
NeurogesX Appoints New Board Director and Audit Committee Chairman
Aug 25, 2009
|
9.9 KB |
|
| |
SAN MATEO, Calif., Aug 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the appointment of Bradford S. Goodwin to its Board of Directors as a director and Audit Committee chairman, effectiv...
|
|
NeurogesX Reports Second Quarter 2009 Results
Aug 7, 2009
|
20.9 KB |
|
| |
SAN MATEO, Calif., Aug 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- 2Q09 Corporate Highlights:
-- Granted European Commission (EC) approval of Qutenza for treatment of
peripheral neuropathic pain in non-diabetic adults, either alone or in
combination with other medicinal products for pain
-- Entered exc...
|
|
NeurogesX Announces New PDUFA Date for Qutenza® New Drug Application
Aug 5, 2009
|
9.8 KB |
|
| |
SAN MATEO, Calif., Aug 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) dat...
|
|
NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
Jul 31, 2009
|
8.9 KB |
|
| |
SAN MATEO, Calif., July 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Friday, August 7, 2009 at 9:00 a.m. ET (6:00 a.m. PT) to report results for its se...
|
|
NeurogesX Announces Preliminary Results of FDA-Requested Qutenza® Study
Jul 24, 2009
|
8.8 KB |
|
| |
SAN MATEO, Calif., July 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- NeurogesX, Inc. (Nasdaq: NGSX) announced today the preliminary results of a short-term clinical study (Study C123) of Qutenza(TM) in patients with postherpetic neuralgia (PHN) following pretreatment with an FDA-approved topical anesthetic. As part of the ongoing new ...
|
|
|
